Abstract
Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.
| Original language | English |
|---|---|
| Journal | The International Journal of Chronic Obstructive Pulmonary Disease (Online) |
| Volume | 7 |
| Pages (from-to) | 673-8 |
| Number of pages | 6 |
| ISSN | 1178-2005 |
| DOIs | |
| Publication status | Published - 2012 |
Fingerprint
Dive into the research topics of 'Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS